<DOC>
	<DOCNO>NCT01958645</DOCNO>
	<brief_summary>A study investigate safety , tolerability pharmacodynamics MEDI8111 single ascending dose healthy male .</brief_summary>
	<brief_title>To Assess Safety , Tolerability Pharmacodynamics Intravenous MEDI8111 After Single Ascending Doses .</brief_title>
	<detailed_description>A phase I , single-blind , randomise , placebo-controlled , single centre study investigate safety , tolerability pharmacodynamics intravenous MEDI8111 single ascending dose healthy male subject .</detailed_description>
	<criteria>Provision sign date , write informed consent prior study specific procedure , Healthy male subject age 1840 year suitable vein cannulation repeat venepuncture , Have body mass index ( BMI ) 18 30 kg/m2 inclusive weight least 50 kg 100 kg inclusive , Male subject willing avoid fathering child either true abstinence use two effective mean contraception day dose 3 month dose IP . They also willing use barrier method day dose 3 month dose . Prothrombotic mutation factor V Leiden , deficiencies protein C , protein S , prothrombin , antithrombin APC , Antibodies coagulation FII , History family history venous arterial thromboembolic event , and/or myocardial infarction age 50 year , ETP level baseline &gt; 2000nM/min , FII level ( clot ) screen and/or baseline outside 50250 % normal range</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Phase 1 , healthy male subject , safety tolerability , pharmacodynamic , pharmacokinetic</keyword>
</DOC>